Canada markets closed

Atai Life Sciences N.V. (ATAI)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
1.1600+0.1000 (+9.43%)
At close: 04:00PM EDT
1.1700 +0.01 (+0.86%)
After hours: 07:54PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close1.0600
Open1.0600
Bid1.1500 x 300
Ask1.1800 x 400
Day's Range1.0600 - 1.1700
52 Week Range1.0250 - 2.8500
Volume825,940
Avg. Volume610,201
Market Cap194.647M
Beta (5Y Monthly)0.78
PE Ratio (TTM)N/A
EPS (TTM)-0.3600
Earnings DateNov 05, 2024 - Nov 12, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est11.60
  • GlobeNewswire

    atai Life Sciences to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

    NEW YORK and BERLIN, Sept. 04, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that the Company’s management team is scheduled to participate in the H.C. Wainwright 26th Annual Global Investment Conference in New York, NY from September 9-11, 2024. Details of the company’s participation: Format: Fireside chat and 1x1 investor meetingsDate and

  • GlobeNewswire

    atai Life Sciences Reports Second Quarter 2024 Financial Results and Provides Corporate Updates

    • Reported positive Phase 1b results of VLS-01 (buccal film DMT); expect to initiate a Phase 2 study in treatment-resistant depression patients around YE’24 • Announced clinical development plans for EMP-01 (oral R-MDMA); expect to initiate a Phase 2 study of EMP-01 in social anxiety disorder patients around YE’24 • Cash, marketable securities, and committed term loan funding expected to fund operations into 2026 NEW YORK and BERLIN, Aug. 13, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ:

  • GlobeNewswire

    atai Life Sciences Announces Positive Preliminary Results from Phase 1b Trial of VLS-01 (Buccal Film DMT)

    VLS-01 is designed to induce a short psychedelic experience, allowing for a total in-clinic treatment of 2-hours, consistent with an established commercial paradigm in interventional psychiatryVLS-01 reached peak plasma concentration within 30-45 minutes and was shown to induce a short psychedelic experience, with subjective effects generally resolving within 90-120 minutesVLS-01 demonstrated a favorable safety profile and was well tolerated, with all adverse events classified as either mild or